Resonant Capital Advisors LLC Buys 119 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Resonant Capital Advisors LLC grew its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 8.5% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,526 shares of the medical equipment provider’s stock after acquiring an additional 119 shares during the quarter. Resonant Capital Advisors LLC’s holdings in Intuitive Surgical were worth $750,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of ISRG. Ullmann Wealth Partners Group LLC boosted its stake in Intuitive Surgical by 1.6% in the 3rd quarter. Ullmann Wealth Partners Group LLC now owns 1,329 shares of the medical equipment provider’s stock worth $653,000 after purchasing an additional 21 shares in the last quarter. One Wealth Management Investment & Advisory Services LLC lifted its stake in shares of Intuitive Surgical by 3.4% in the second quarter. One Wealth Management Investment & Advisory Services LLC now owns 697 shares of the medical equipment provider’s stock worth $310,000 after buying an additional 23 shares in the last quarter. Daymark Wealth Partners LLC lifted its stake in shares of Intuitive Surgical by 0.3% in the third quarter. Daymark Wealth Partners LLC now owns 7,027 shares of the medical equipment provider’s stock worth $3,452,000 after buying an additional 24 shares in the last quarter. Indiana Trust & Investment Management CO increased its position in shares of Intuitive Surgical by 5.3% during the second quarter. Indiana Trust & Investment Management CO now owns 500 shares of the medical equipment provider’s stock valued at $222,000 after acquiring an additional 25 shares in the last quarter. Finally, Hoxton Planning & Management LLC increased its position in shares of Intuitive Surgical by 4.9% during the second quarter. Hoxton Planning & Management LLC now owns 534 shares of the medical equipment provider’s stock valued at $238,000 after acquiring an additional 25 shares in the last quarter. 83.64% of the stock is owned by hedge funds and other institutional investors.

Intuitive Surgical Stock Up 10.0 %

ISRG stock opened at $521.15 on Monday. The business’s 50-day moving average price is $483.85 and its 200-day moving average price is $438.56. The stock has a market cap of $184.85 billion, a P/E ratio of 94.07, a PEG ratio of 5.40 and a beta of 1.39. Intuitive Surgical, Inc. has a twelve month low of $254.85 and a twelve month high of $523.34.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.24. The business had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $1.97 billion. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The company’s revenue for the quarter was up 14.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.18 earnings per share. On average, equities research analysts expect that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have commented on the company. Barclays increased their target price on Intuitive Surgical from $430.00 to $490.00 and gave the company an “overweight” rating in a research note on Thursday, July 18th. JPMorgan Chase & Co. boosted their target price on Intuitive Surgical from $495.00 to $575.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Morgan Stanley raised their price target on shares of Intuitive Surgical from $375.00 to $460.00 and gave the company an “equal weight” rating in a report on Monday, July 15th. Piper Sandler reissued an “overweight” rating and set a $538.00 price objective (up from $495.00) on shares of Intuitive Surgical in a report on Friday. Finally, Stifel Nicolaus lifted their target price on shares of Intuitive Surgical from $475.00 to $525.00 and gave the stock a “buy” rating in a research report on Friday. One investment analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $513.74.

Insider Activity

In related news, EVP Robert Desantis sold 188 shares of the company’s stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $482.21, for a total value of $90,655.48. Following the completion of the transaction, the executive vice president now owns 5,506 shares of the company’s stock, valued at approximately $2,655,048.26. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other Intuitive Surgical news, EVP Robert Desantis sold 188 shares of the company’s stock in a transaction that occurred on Thursday, August 29th. The stock was sold at an average price of $482.21, for a total value of $90,655.48. Following the completion of the transaction, the executive vice president now directly owns 5,506 shares in the company, valued at $2,655,048.26. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Craig H. Barratt sold 1,400 shares of Intuitive Surgical stock in a transaction that occurred on Tuesday, July 23rd. The shares were sold at an average price of $458.13, for a total transaction of $641,382.00. The disclosure for this sale can be found here. Insiders have sold 53,120 shares of company stock worth $25,528,753 in the last three months. Company insiders own 0.90% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.